Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phensedyl is an oral cough and cold syrup brand containing the opioid antitussive codeine phosphate and the first-generation antihistamine promethazine hydrochloride, or in some linctus formulations codeine phosphate with the antihistamine chlorpheniramine maleate. These components act synergistically to suppress the cough reflex via central μ‑opioid receptor activity, reduce histamine-mediated upper respiratory symptoms through H1-receptor blockade, and provide mild sedative effects that can alleviate associated discomfort. The product is indicated for short-term relief of dry, non‑productive cough and allergic cold symptoms such as runny nose, sneezing, and throat irritation, but carries risks of respiratory depression, sedation, constipation, and dependence due to codeine, and anticholinergic and sedative adverse effects from the antihistamine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Phensedyl.